EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study

Iman Menbari Oskouie, Fatemeh Khatami iD, Amin Shiralizadeh Dezfuli, Rahil Mashhadi, Akram Mirzaei, Seyedeh Negin Hashemi Dougaheh, Helia Azodian Ghajar, Ramin Heshmat, Seyed Mohammad Kazem Aghamir iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0318483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Iman Menbari Oskouie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Flutamide, Selenium, Prostatic Neoplasms, Nanoparticles. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Objective of the study was to evaluate the therapeutic potential of selenium nanoparticles (SeNPs) in combination with flutamide for treating prostate cancer (PCa) cell lines. The goal was to reduce the dosage of flutamide to decrease its side effects, especially hepatotoxicity. Materials and methods PC3, LnCAP, and DU145 cell lines were treated with varying concentrations of SeNPs and Flutamide to determine IC50 values using the MTT assay. Subsequently, the IC50 concentration of flutamide was reduced by 50% and different concentrations of SeNPs were added to determine new IC50 concentrations of the combinations. Annexin-V/ PI staining was performed to assess the apoptosis rate. The DNA cell cycle was analyzed using the PI staining technique. Migration, proliferative capability, and nucleus morphology of the cells were evaluated through the scratch-wound assay, colony-forming assay, and Hoechst staining, respectively. The expression of SNAIL , KLK3 , E-cadherin , VEGF-C , HIF-1α , Bcl2 , and BAX were examined using real-time PCR.

Results

All treated groups significantly increased early and late apoptosis rate of the PCa cell lines, and induced SubG1/G1 arrest in the cell cycle assay, compared to the control group. Significant inhibition of migration potential and colony formation was observed in all treated groups. Our results suggest that the combination group (50% decrease of Flutamide dosage) treatment upregulated apoptosis-related genes and KLK3 , and downregulated genes involved in angiogenesis and proliferation similar to Flutamide alone (p > 0.05).

Conclusion

It is suggested that simultaneous administration of SeNPs and flutamide could potentially reduce the effective dosage of flutamide and decrease its adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlutamideSeleniumProstatic NeoplasmsNanoparticlesHumansMaleCell Line, TumorApoptosisCell ProliferationCell MovementCell Cycle

Substanzen

FlutamideSelenium

Autor:innen und Institutionen

  • Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ronash Technology Pars Company (AMINBIC), Tehran University Science and Technology Park, North Campus of Tehran University, Tehran, Iran.
  • Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Fatemeh Khatami, Seyed Mohammad Kazem Aghamir

Zitieren

APA

Menbari Oskouie, I., Khatami, F., Shiralizadeh Dezfuli, A., Mashhadi, R., Mirzaei, A., Hashemi Dougaheh, S. N., Azodian Ghajar, H., Heshmat, R., & Aghamir, S. M. K. (2025). Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study. PLOS One. https://doi.org/10.1371/journal.pone.0318483

Vancouver

Menbari Oskouie I, Khatami F, Shiralizadeh Dezfuli A, Mashhadi R, Mirzaei A, Hashemi Dougaheh SN, et al. Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study. PLOS One. 2025. doi:10.1371/journal.pone.0318483

BibTeX
@article{MenbariOskouie2025,
  author = {Menbari Oskouie, Iman and Khatami, Fatemeh and Shiralizadeh Dezfuli, Amin and Mashhadi, Rahil and Mirzaei, Akram and Hashemi Dougaheh, Seyedeh Negin and Azodian Ghajar, Helia and Heshmat, Ramin and Aghamir, Seyed Mohammad Kazem},
  title = {Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0318483}
}
Kostenlos starten →